Milast-A Tablet 500 mcg contains Roflumilast, a selective phosphodiesterase-4 (PDE4) inhibitor designed to reduce inflammation in the airways and improve lung function in patients with chronic respiratory diseases. Milast-A is primarily indicated for the management of chronic obstructive pulmonary disease (COPD), particularly in patients with severe symptoms and a history of frequent exacerbations.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Phosphodiesterase-4 (PDE4) Inhibitor / Anti-inflammatory Agent

Indications

Milast-A Tablet 500 mcg is indicated for:

• Management of severe chronic obstructive pulmonary disease (COPD)

• Reduction of the risk of exacerbations in patients with chronic bronchitis associated with COPD

• Adjunct therapy for patients not adequately controlled with standard bronchodilators

Pharmacology

Roflumilast, the active ingredient in Milast-A, works by inhibiting the PDE4 enzyme, which plays a key role in inflammatory processes in the lungs. By blocking PDE4, Roflumilast increases cyclic adenosine monophosphate (cAMP) levels in inflammatory cells, leading to:

• Reduction of airway inflammation

• Decreased release of pro-inflammatory mediators

• Improved airflow and respiratory function
  This targeted mechanism helps reduce the frequency of COPD exacerbations and promotes better symptom control.

Dosage and Administration

• Recommended adult dose: 500 mcg, orally, once daily

• Can be taken with or without food

• Swallow the tablet whole with water; do not crush or chew

• Treatment should be continued regularly for optimal benefits

• Monitor clinical response and tolerability, particularly in patients with weight loss or depression

Side Effects

Common side effects include:

• Diarrhea

• Nausea or vomiting

• Headache

• Weight loss

• Insomnia

Less common but serious side effects:

• Psychiatric effects such as depression, anxiety, or suicidal thoughts

• Severe gastrointestinal symptoms

• Hypersensitivity reactions (rash, itching, swelling)

Contraindications

• Known hypersensitivity to Roflumilast or any component of the tablet

• Moderate to severe liver impairment

• Severe psychiatric disorders

Precautions & Warnings

• Use with caution in patients with depression or history of suicidal thoughts

• Monitor weight regularly, as significant weight loss may occur

• Not intended as a rescue medication for acute COPD exacerbations

• Safety and efficacy in children and adolescents have not been established

• Use during pregnancy and lactation only if clearly needed and prescribed by a physician

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

• Caution with CYP3A4 and CYP1A2 inducers or inhibitors, as they may alter Roflumilast plasma levels

• Avoid concomitant use with strong enzyme inducers such as rifampicin, phenobarbital, or carbamazepine

Storage

• Store in a cool, dry place below 30°C

• Protect from light and moisture

• Keep out of reach of children

Mode of Action

Roflumilast in Milast-A Tablet 500 mcg selectively inhibits PDE4 in airway inflammatory cells, increasing cAMP levels and reducing inflammation. This mechanism helps prevent COPD exacerbations, improves airflow, and supports better long-term respiratory function.